Jessica N Haladyna

Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.

A. Perraud, K. Bernt, Simone S. Riedel, 2016, Experimental hematology.

Epigenetic modifiers in normal and malignant hematopoiesis.

T. Neff, K. Bernt, Jessica N Haladyna, 2015, Epigenomics.

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia

S. Armstrong, S. Orkin, T. Neff, 2016, Cell reports.

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma

U. Dirksen, A. Üren, J. Toretsky, 2017, Science Signaling.

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia

David A. Drubin, E. Olhava, R. Copeland, 2017, Molecular Cancer Therapeutics.

Menin is necessary for long term maintenance of meningioma-1 driven leukemia

H. Xie, Fatemeh Alikarami, K. Bernt, 2021, Leukemia.

MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Scott A. Armstrong, Daniel A. Pollyea, Craig T. Jordan, 2016, The Journal of clinical investigation.

Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.

S. Armstrong, S. Orkin, T. Neff, 2015, Experimental hematology.